82 FR 51433 - Notice Pursuant to the National Cooperative Research and Production Act of 1993-Medical Technology Enterprise Consortium

DEPARTMENT OF JUSTICE
Antitrust Division

Federal Register Volume 82, Issue 213 (November 6, 2017)

[Federal Register Volume 82, Number 213 (Monday, November 6, 2017)]
[Notices]
[Page 51433]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-24101]



[[Page 51433]]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Medical Technology Enterprise Consortium

    Notice is hereby given that, on September 29, 2017, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Medical Technology 
Enterprise Consortium (``MTEC'') has filed written notifications 
simultaneously with the Attorney General and the Federal Trade 
Commission disclosing changes in its membership. The notifications were 
filed for the purpose of extending the Act's provisions limiting the 
recovery of antitrust plaintiffs to actual damages under specified 
circumstances. Specifically, 2C4 Technologies, Inc., San Antonio, TX; 
Actuated Medical, Inc., Bellefonte, PA; American Type Culture 
Collection (ATCC Federal Solutions), Manassas, VA; Amethyst 
Technologies, LLC, Baltimore, MD; Anu Life Sciences, Sunrise, FL; 
Arteriocyte, Inc. d/b/a/Compass Biomedical, Hopkinton, MA; Charles 
River Analytics, Inc., Cambridge, MA; Chimerix, Inc., Durham, NC; Cole 
Engineering Services, Inc., Orlando, FL; Corvid Technologies, 
Mooresville, NC; Daxor Corporation, New York, NY; Elemance, LLC, 
Clemmons, NC; Emergent BioSolutions, Gaithersburg, MD; Human Biomed, 
Inc., South Burlington, VT; L-3 Applied Technologies, Inc., San Diego, 
CA; LifeLink Foundation, Inc., Tampa, FL; MalarVx, Inc., Seattle, WA; 
Manzanita Pharmaceuticals, Inc., Woodside, CA; Medtronic, Minneapolis, 
MN; Melinta Therapeutics, Inc., New Haven, CT; Neuroplast BV, 
Maastricht, NETHERLANDS; Platelet BioGenesis, Inc., Boston, MA; 
RegeniSource LLC, San Antonio, TX; Remedor Biomed Ltd., Nazareth lllit, 
ISRAEL; Roccor, LLC, Longmont, CO; Soar Technology, Inc., Ann Arbor, 
MI; SynDaver Labs, Tampa, FL; The Board of Supervisors of Louisiana 
State University and Agricultural & Mechanical College herein 
represented by Louisiana State University Health Sciences Center in New 
Orleans (LSUHSC), New Orleans, LA; The Medical College of Wisconsin, 
Inc., Milwaukee, WI; The Metis Foundation, San Antonio, TX; University 
of Iowa, Iowa city, IA; University of Maryland, College Park, MD; 
Vcom3D, Inc., Orlando, FL, and Vivacelle Bio, Inc., Chicago, IL have 
been added as parties to this venture.
    Also, Applied Medical Device Institute (aMDI)--Grand Valley State 
University, Grand Rapids, MI; Aptus, LLC, Clemson, SC; Ellipsis 
Technologies, Inc., Greenville, SC; Johns Hopkins University, 
Baltimore, MD; Longeveron LLC, Miami, FL; Lovelace Biomedical and 
Environmental Research Institute, Albuquerque, NM; MicroCures, Inc., 
Santa Cruz, CA; New York Institute of Technology, Old Westbury, NY; 
NGT-VC 2012 Limited Partnership (NGT3), Nazareth, ISRAEL; and Otologic 
Pharmaceutics Inc., Oklahoma City, OK, have withdrawn as parties to 
this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and MTEC intends to file additional 
written notifications disclosing all changes in membership.
    On May 9, 2014, MTEC filed its original notification pursuant to 
Section 6(a) of the Act. The Department of Justice published a notice 
in the Federal Register pursuant to Section 6(b) of the Act on June 9, 
2014 (79 FR 32999).
    The last notification was filed with the Department on June 23, 
2017. A notice was published in the Federal Register pursuant to 
Section 6(b) of the Act on August 15, 2017(82 FR 38708).

Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2017-24101 Filed 11-3-17; 8:45 am]
 BILLING CODE P